Chk2 (CHEK2) Human Gene Knockout Kit (CRISPR)

CAT#: KN201278RB

CHEK2 - human gene knockout kit via CRISPR, HDR mediated

Product Images

Specifications

Product Data

• Format: 2 gRNA vectors, 1 RFP-BSD donor, 1 scramble control
• Donor DNA: RFP-BSD
• Symbol: Chk2
• Locus ID: 11200
• Components:

  KN201278G1, Chk2 gRNA vector 1 in pCas-Guide CRISPR vector

  KN201278G2, Chk2 gRNA vector 2 in pCas-Guide CRISPR vector

  KN201278RBD, donor DNA containing left and right homologous arms and RFP-BSD functional cassette.

  GE100003, scramble sequence in pCas-Guide vector

• Disclaimer: These products are manufactured and supplied by OriGene under license from ERS. The kit is designed based on the best knowledge of CRISPR technology. The system has been functionally validated for knocking-in the cassette downstream the native promoter. The efficiency of the knock-out varies due to the nature of the biology and the complexity of the experimental process.

Reference Data

• RefSeq: NM_001005735, NM_001257387, NM_007194, NM_145862, NM_001349956
• UniProt ID: O96017
• Synonyms: CDS1; CHK2; hCds1; HuCds1; LFS2; PP1425; RAD53
• Summary: In response to DNA damage and replication blocks, cell cycle progression is halted through the control of critical cell cycle regulators. The protein encoded by this gene is a cell cycle checkpoint regulator and putative tumor suppressor. It contains a forkhead-associated protein interaction domain essential for activation in response to DNA damage and is rapidly phosphorylated in response to replication blocks and DNA damage. When activated, the encoded protein is known to inhibit CDC25C phosphatase, preventing entry into mitosis, and has been shown to stabilize the tumor suppressor protein p53, leading to cell cycle arrest in G1. In addition, this protein interacts with and phosphorylates BRCA1, allowing BRCA1 to restore survival after DNA damage. Mutations in this gene have been linked with Li-Fraumeni syndrome, a highly penetrant familial cancer phenotype usually associated with inherited mutations in TP53. Also, mutations in this gene are thought to confer a predisposition to sarcomas, breast cancer, and brain tumors. This nuclear protein is a member of the CDS1 subfamily of serine/threonine protein kinases. Several transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Apr 2012]